SCHEMBL771410

SCHEMBL771410

O=C(CNC(=S)NCC1CCCCC1)N1CCC2CCCC=C2C1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.35
MAPT P10636 3/20 0.35
TDP1 Q9NUW8 1/20 0.35
KMT2A Q03164 5/20 0.34
CA2 P00918 2/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
MMP1 P03956 1/20 0.33
MMP2 P08253 1/20 0.33
MMP3 P08254 1/20 0.33
MMP9 P14780 1/20 0.33
MMP8 P22894 1/20 0.33
CA9 Q16790 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
HTT P42858 2/20 0.33
NAMPT P43490 1/20 0.33
HPGD P15428 1/20 0.33
ALOX12 P18054 1/20 0.33
MLYCD O95822 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL771107 0.87 ADAMTS4 (0.36) KMT2AMMP8NAMPTHDAC6EPHX1
SCHEMBL771342 0.86 ALDH1A1 (0.40) ALDH1A1MAPTTDP1SMN1; SMN2ALOX12
SCHEMBL770476 0.85 ALDH1A1 (0.38) ALDH1A1MAPTTDP1KMT2ASMN1; SMN2
SCHEMBL770590 0.82 HTT (0.37) ALDH1A1KMT2AHTTMEN1POLB
SCHEMBL772432 0.81 ALDH1A1 (0.46) ALDH1A1MAPTKMT2ASMN1; SMN2HTT
SCHEMBL15378203 0.79 EPHX2 (0.40) ALDH1A1MAPTSMN1; SMN2HTTALOX12
SCHEMBL771006 0.79 EPHX1 (0.46) ALDH1A1MAPTTDP1SMN1; SMN2HPGD
SCHEMBL15380799 0.79 EPHX1 (0.46) ALDH1A1MAPTTDP1SMN1; SMN2HPGD
SCHEMBL770629 0.78 TACR1 (0.38) ALDH1A1MAPTTDP1KMT2ASMN1; SMN2
SCHEMBL771027 0.77 PPID (0.35) ALDH1A1MAPTTDP1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 ALDH1A1 144/4885MAPT 618/4885TDP1 135/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 ALDH1A1 142/4885MAPT 638/4885TDP1 134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.